[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neumora Therapeutics Inc (NMRA)

Neumora Therapeutics Inc (NMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 329,806
  • Shares Outstanding, K 185,284
  • Annual Sales, $ 0 K
  • Annual Income, $ -236,930 K
  • EBIT $ -223 M
  • EBITDA $ -225 M
  • 60-Month Beta 2.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.60

Options Overview Details

View History
  • Implied Volatility 286.64% (-19.41%)
  • Historical Volatility 85.77%
  • IV Percentile 87%
  • IV Rank 48.88%
  • IV High 536.33% on 02/05/26
  • IV Low 47.87% on 09/03/25
  • Expected Move (DTE 4) 0.5525 (31.04%)
  • Put/Call Vol Ratio 4.02
  • Today's Volume 602
  • Volume Avg (30-Day) 1,360
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 70,747
  • Open Int (30-Day) 63,164
  • Expected Range 1.2275 to 2.3325

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 4
  • High Estimate $-0.20
  • Low Estimate $-0.30
  • Prior Year $-0.33
  • Growth Rate Est. (year over year) +30.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5700 +13.38%
on 06/10/26
1.9850 -10.33%
on 05/14/26
-0.1200 (-6.32%)
since 05/12/26
3-Month
1.5700 +13.38%
on 06/10/26
3.2650 -45.48%
on 03/13/26
-1.3600 (-43.31%)
since 03/12/26
52-Week
0.7158 +148.67%
on 06/30/25
3.6500 -51.23%
on 02/18/26
+0.8800 (+97.78%)
since 06/12/25

Most Recent Stories

More News
SoftBank Just Dumped Circle Stock. Don’t Panic and Keep Adding CRCL Here.

SoftBank fully exited Circle Internet Group in Q1 2026. Here is what investors need to know about the stablecoin giant's fundamentals.

TMUS : 189.10 (+1.77%)
BLK : 1,032.00 (+1.52%)
META : 566.98 (-0.26%)
LMND : 57.49 (+0.54%)
CRCL : 77.84 (-5.80%)
SFTBY : 21.9100 (+0.74%)
NMRA : 1.7800 (unch)
ICE : 140.53 (+1.12%)
^USDCUSD : 1.000080 (unch)
UBER : 68.85 (-1.01%)
DASH : 150.58 (-2.59%)
LIFE : 15.61 (-9.14%)
Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target...

NMRA : 1.7800 (unch)
Neumora's Pipeline Credibility Rests on Two Readouts Due Within Weeks

Barchart Research What to Expect from NMRA Earnings NMRA Generated May 8, 2026 Current Price $1.8300 EPS Estimate $$-0.25 Consensus Rating Moderate Buy Average Move 7.45% Neumora's Pipeline Credibility...

NMRA : 1.7800 (unch)
Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer’s disease agitation...

NMRA : 1.7800 (unch)
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference

WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc.  (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that...

NMRA : 1.7800 (unch)
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies  KOASTAL-2 and -3 fully enrolled in the first quarter of...

NMRA : 1.7800 (unch)
Neumora Therapeutics Has Been Quietly Cutting Losses. Monday, We Find Out If Anyone's Paying Attention.

Barchart Research What to Expect from NMRA Earnings NMRA Generated March 27, 2026 Current Price $2.33 EPS Estimate $-0.34 Consensus Rating Moderate Buy Average Move 5.71% Neumora Therapeutics Has Been...

NMRA : 1.7800 (unch)
Neumora Therapeutics Has Been Quietly Cutting Losses. Monday, We Find Out If Anyone's Paying Attention.

Barchart Research What to Expect from NMRA Earnings NMRA Generated March 27, 2026 Current Price $2.33 EPS Estimate $-0.34 Consensus Rating Moderate Buy Average Move 5.71% Neumora Therapeutics Has Been...

NMRA : 1.7800 (unch)
Neumora Therapeutics Has Been Quietly Cutting Losses. Monday, We Find Out If Anyone's Paying Attention.

Barchart Research What to Expect from NMRA Earnings NMRA Generated March 27, 2026 Current Price $2.33 EPS Estimate $-0.34 Consensus Rating Moderate Buy Average Move 5.71% Neumora Therapeutics Has Been...

NMRA : 1.7800 (unch)
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Neumora Therapeutics, Inc. (“Neumora” or “the Company”)...

NMRA : 1.7800 (unch)

Business Summary

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. Its therapeutic pipeline currently consists of clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora...

See More

Key Turning Points

3rd Resistance Point 1.9067
2nd Resistance Point 1.8733
1st Resistance Point 1.8267
Last Price 1.7800
1st Support Level 1.7467
2nd Support Level 1.7133
3rd Support Level 1.6667

See More

52-Week High 3.6500
Fibonacci 61.8% 2.5291
Fibonacci 50% 2.1829
Fibonacci 38.2% 1.8367
Last Price 1.7800
52-Week Low 0.7158

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.